Medimabbio

Developer of immunotherapeutics for treating cancer

placeSeongnam-si, Gyeonggi-do, South Korea calendar_todayFounded 2017 groups19 employees language medimabbio.com

Innovation

6 patent families (1 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace accelerating. Cited 120 times.

YearFilings
20222
20234
20242
20254
20262

Social engagement

Social engagement: 571 social following, 4 posts in the last 12 months — below the industry typical range.

Investor mix

16 investors on record; lead investors include KB Investment.

Investor typeCountShare
Venture capital1063%
Private equity16%
Other / undisclosed531%

Recent activity

19 Dec 2025
Event
JPM Week 2026
23 Oct 2025
Recognition
23 Oct 2025
Event
BIO-Europe Fall 2025
Coming soon